149 related articles for article (PubMed ID: 6687657)
1. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer.
Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
6. Phase II clinical evaluation of AZQ in colorectal cancer.
Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
[TBL] [Abstract][Full Text] [Related]
7. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
11. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
14. Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy.
Legha SS; Latreille J; McCredie KB; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2001-3. PubMed ID: 526933
[No Abstract] [Full Text] [Related]
15. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m--anisidine (AMSA) in patients with advanced head and neck cancers.
Ratanatharathorn V; Drelichman A; Sexon-Porte M; Al-Sarraf M
Am J Clin Oncol; 1982 Feb; 5(1):29-32. PubMed ID: 6896258
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein JR; Karlin DA; Bennetts RW; Stewart DJ; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):49-52. PubMed ID: 6837507
[TBL] [Abstract][Full Text] [Related]
19. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
20. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]